Zydus Cadila Seeks Nod For Phase Three Clinical Trials Of Covid Vaccine

Zydus Cadila on Thursday submitted data from phase one and two clinical trials for its coronavirus vaccine ZyCov-D and sought approval for the next phase of tests.

The vaccine was found to be safe and well tolerated in tests on more than a thousand healthy adult volunteers, said the company, adding phase three clinical trial in around 30,000 volunteers upon receiving necessary approvals.

The multi-centre and randomized trials were reviewed by an independent Data Safety Monitoring Board (DSMB). Reports have been submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

Zydus Group chairperson Pankaj Patel said that company is optimistic of the phase III clinical trial outcomes as well. "We would be able to start production of the novel vaccine on its successful completion," he said.

The DNA platform used in ZyCoV-D improves the vaccine’s stability, lowering cold chain requirements and making it usable in remotest regions of the country. Administered through the intradermal route, it also allows for the ease of administration.

Further, the platform also provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1). The platform can be used to modify the vaccine in couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.

The plasmid DNA when introduced into the host cells would be translated into the viral protein and will elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance. National Biopharma Mission, BIRAC, Department of Biotechnology, ICMR and NIV Pune have also supported the development of ZyCoV-D, the company acknowledged.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor